PDE5 Inhibitor Composition for Selective PTSD Fear Memory Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for post-traumatic stress disorder (PTSD) such as selective serotonin reuptake inhibitors (SSRIs) have adverse effects that limit their long-term use, necessitating the development of safer and more effective drugs.

Innovation Solution

Phosphodiesterase type 5 (PDE5) inhibitors, including mirodenafil, sildenafil, and tadalafil, are used to selectively inhibit contextual fear memory in trauma-exposed models while preserving novel object recognition and spatial memory functions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If SSRIs such as fluoxetine are used to treat PTSD, then therapeutic efficacy is improved, but adverse effects including cognitive impairment, weight gain, sexual dysfunction, sedation, drug dependence, and withdrawal symptoms occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from SSRIs to PDE5 inhibitors, which have a different mechanism of action. PDE5 inhibitors work by blocking the breakdown of cGMP, leading to increased cGMP levels that reduce fear memory without the adverse effects associated with SSRIs. This parameter change resolves the contradiction by providing therapeutic efficacy through a different pharmacological class with a more favorable side effect profile.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PDE5 inhibitors are used to block contextual fear memory, then PTSD symptoms are improved, but cognitive impairment may occur

Engineering Contradiction:

ImprovePTSD treatment effectVSAvoidcognitive function

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent applies local quality by demonstrating that PDE5 inhibitors selectively block contextual fear memory while preserving other cognitive functions such as novel object recognition and spatial memory. This selective action is achieved through the specific pharmacological properties of PDE5 inhibitors that target fear conditioning pathways without affecting other cognitive processes, thus resolving the contradiction between treating PTSD and maintaining cognitive function.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

PDE5 inhibitors effectively block context-specific fear memories associated with PTSD without impairing cognitive abilities, offering a potential therapeutic option for PTSD treatment.

Implementation Method 1

phosphodiesterase type 5 (PDE 5) inhibitors, including mirodenafil, sildenafil, and tadalafil, can selectively inhibit contextual fear memory

Methodology Applied

Scientific EffectPhosphodiesterase inhibition: Enzyme

Data Source

PatentEP4656194A1Composition for preventing or treating post-traumatic stress disorder, comprising phosphodiesterase type 5 inhibitor as active ingredient

Publication Date: 2025.12.03 ARIBIO CO LTD

Figure 1
Figure 2
Figure 3

AI summary

The present invention relates to a composition for preventing or treating post-traumatic stress disorder, comprising a phosphodiesterase type 5 (PDE 5) inhibitor as an active ingredient, and, particularly, to: a pharmaceutical composition or a health functional food composition for preventing, improving or treating post-traumatic stress disorder, comprising a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient; and a method for preventing or treating post-traumatic stress disorder, comprising a step of administering the pharmaceutical composition to an individual.